Patents by Inventor David Reifsnyder
David Reifsnyder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20050037475Abstract: Highly purified preparations of TFPI or TFPI analogs can be prepared using a method that generally involves the following steps: (1) expression of TFPI or TFPI analog in E. coli, (2) isolation of refractile bodies, (3) dissolution of the refractile bodies and refolding of the expressed TFPI or TFPI analog, (4) SP-Sepharose fast flow (FF) chromatography, (5) a first concentration and diafiltration step, (6) Q-Sepharose high (HP) performance chromatography, (7) butyl hydrophobic interaction chromatography (HIC), (8) SP-Sepharose HP chromatography, and (9) a second concentration/diafiltration step. Less than about 12% of the TFPI or TFPI analog molecules in such preparations are modified TFPI or TFPI analog species (i.e., oxidized, carbamylated, acetylated, deamidated, aggregated, or misfolded species).Type: ApplicationFiled: January 8, 2004Publication date: February 17, 2005Applicants: Chiron Corporation, Pharmacia & Upjohn CompanyInventors: David Reifsnyder, Duane Inlow, Glenn Dorin, Patricio Riquelme, Cynthia Cowgill, Douglas Bolesch, Mark Gustafson
-
Patent number: 6265542Abstract: A process for purifying molecules from contaminants is provided. In this process a mixture containing the molecule (peptide, polypeptide, or biologically active non-peptidyl compound) and its contaminants is loaded onto a reversed-phase liquid chromatography column and the molecule is eluted from the column with a buffer containing hexylene glycol.Type: GrantFiled: October 8, 1998Date of Patent: July 24, 2001Assignee: Genentech, Inc.Inventors: Robert Lee Fahrner, David Reifsnyder
-
Patent number: 5808006Abstract: A composition is provided comprising about 0.1 to 15 mg/ml of a polypeptide in a buffer having a pH of about 7-12 comprising about 5-40% (v/v) of an alcoholic or polar aprotic solvent, about 0.2 to 3M of an alkaline earth, alkali metal, or ammonium salt, about 0.1 to 9M of a chaotropic agent, and about 0.01 to 15 .mu.M of a copper or manganese salt. The buffer is suitably used in a method for refolding improperly folded polypeptides.Type: GrantFiled: October 11, 1994Date of Patent: September 15, 1998Assignee: Genentech, Inc.Inventors: Stuart Builder, Roger Hart, Philip Lester, David Reifsnyder
-
Patent number: 5756672Abstract: A composition is provided comprising about 0.1 to 15 mg/mL of a polypeptide in a buffer having a pH of about 7-12 comprising about 5-40% (v/v) of an alcoholic or polar aprotic solvent, about 0.2 to 3M of an alkaline earth, alkali metal, or ammonium salt, about 0.1 to 9M of a chaotropic agent, and about 0.01 to 15 .mu.M of a copper or manganese salt. The buffer is suitably used in a method for refolding improperly folded polypeptides.Type: GrantFiled: June 6, 1995Date of Patent: May 26, 1998Assignee: Genentech, Inc.Inventors: Stuart Builder, Roger Hart, Philip Lester, David Reifsnyder
-
Patent number: 5723310Abstract: A method is described for isolating an exogenous polypeptide in a non-native conformation from cells, such as an aqueous fermentation broth, in which it is prepared comprising contacting the polypeptide with a chaotropic agent and preferably a reducing agent and with phase-forming species to form multiple aqueous phases, with one of the phases being enriched in the polypeptide and depleted in the biomass solids and nucleic acids originating from the cells. Preferably, the method results in two aqueous phases, with the upper phase being enriched in the polypeptide.Type: GrantFiled: February 7, 1995Date of Patent: March 3, 1998Assignee: Genentech, Inc.Inventors: Stuart Builder, Roger Hart, Philip Lester, John Ogez, David Reifsnyder
-
Patent number: 5695958Abstract: A method is described for isolating an exogenous polypeptide in a non-native conformation from cells, such as an aqueous fermentation broth, in which it is prepared comprising contacting the polypeptide with a chaotropic agent and preferably a reducing agent and with phase-forming species to form multiple aqueous phases, with one of the phases being enriched in the polypeptide and depleted in the biomass solids and nucleic acids originating from the cells. Preferably, the method results in two aqueous phases, with the upper phase being enriched in the polypeptide.Type: GrantFiled: May 17, 1995Date of Patent: December 9, 1997Assignee: Genentech, Inc.Inventors: Stuart Builder, Roger Hart, Philip Lester, John Ogez, David Reifsnyder
-
Patent number: 5663304Abstract: A composition is provided comprising about 0.1 to 15 mg/mL of a polypeptide in a buffer having a pH of about 7-12 comprising about 5-40% (v/v) of an alcoholic or polar aprotic solvent, about 0.2 to 3M of an alkaline earth, alkali metal, or ammonium salt, about 0.1 to 9M of a chaotropic agent, and about 0.01 to 15 .mu.M of a copper or manganese salt. The buffer is suitably used in a method for refolding improperly folded polypeptides.Type: GrantFiled: August 20, 1993Date of Patent: September 2, 1997Assignee: Genentech, Inc.Inventors: Stuart Builder, Roger Hart, Philip Lester, David Reifsnyder
-
Patent number: 5451660Abstract: A process is provided for selectively separating a polypeptide of interest from components of differing hydrophobicity in a mixture comprising the steps of:(a) passing the mixture through underivatized silica particles such that the polypeptide adheres to the silica particles;(b) washing the silica particles to remove impurities; and(c) eluting the polypeptide from the silica particles with a buffer comprising an alcoholic or polar aprotic solvent and an alkaline earth, an alkali metal, or an inorganic ammonium salt.Type: GrantFiled: December 13, 1993Date of Patent: September 19, 1995Assignee: Genentech, Inc.Inventors: Stuart E. Builder, Charles V. Olson, David Reifsnyder
-
Patent number: 5446024Abstract: A process for purifying IGF-I from variants of IGF-I is provided. In this process a mixture containing IGF-I and its variants is loaded onto a reversed-phase liquid chromatography column and the IGF-I is eluted from the column with a buffer at a pH of about 6-8. The buffer contains an alcoholic or polar aprotic solvent at a concentration of about 20-30% (v/v). This process can be preceded by a hydrophobic-interaction chromatography step.Type: GrantFiled: December 17, 1993Date of Patent: August 29, 1995Assignee: Genentech, Inc.Inventors: Stuart E. Builder, John R. Ogez, Charles V. Olson, David Reifsnyder
-
Patent number: 5407810Abstract: A method is described for isolating an exogenous polypeptide in a non-native conformation from cells, such as an aqueous fermentation broth, in which it is prepared comprising contacting the polypeptide with a chaotropic agent and preferably a reducing agent and with phase-forming species to form multiple aqueous phases, with one of the phases being enriched in the polypeptide and depleted in the biomass solids and nucleic acids originating from the cells. Preferably, the method results in two aqueous phases, with the upper phase being enriched in the polypeptide.Type: GrantFiled: August 20, 1993Date of Patent: April 18, 1995Assignee: Genentech, Inc.Inventors: Stuart Builder, Roger Hart, Philip Lester, John Ogez, David Reifsnyder